Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H1 2017’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Toll Like Receptor 8 (CD288 or TLR8)Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Respiratory and Musculoskeletal Disorders under development targeting Toll Like Receptor 8 (CD288 or TLR8)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Dynavax Technologies Corp

Galderma SA

Gilead Sciences Inc

Idera Pharmaceuticals Inc

Janus Biotherapeutics Inc

MedImmune LLC

VentiRx Pharmaceuticals Inc

Vivelix Pharmaceuticals Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8) - Overview

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development

Dynavax Technologies Corp

Galderma SA

Gilead Sciences Inc

Idera Pharmaceuticals Inc

Janus Biotherapeutics Inc

MedImmune LLC

VentiRx Pharmaceuticals Inc

Vivelix Pharmaceuticals Ltd

Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles

854-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DV-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9688 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-8400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-9200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JB-6121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-9197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

motolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-1463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-763 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones

Featured News & Press Releases

Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus

Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination

May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference

Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study

Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis

Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting

May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors

Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer

Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma

Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia

Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting

Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings

Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Dynavax Technologies Corp, H1 2017

Pipeline by Galderma SA, H1 2017

Pipeline by Gilead Sciences Inc, H1 2017

Pipeline by Idera Pharmaceuticals Inc, H1 2017

Pipeline by Janus Biotherapeutics Inc, H1 2017

Pipeline by MedImmune LLC, H1 2017

Pipeline by VentiRx Pharmaceuticals Inc, H1 2017

Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports